Novo Nordisk stock market plunge drags down Swiss device maker Ypsomed - Swissinfo

Novo Nordisk's stock dropped over 20% due to disappointing results from a new drug study, affecting Ypsomed's share price. The study showed CagriSema led to 22.7% weight loss, below the expected 25%, despite Novo Nordisk's optimism.